Originally posted by graphicgr8s What about Britain? Women can't even get the drug for breast cancer anymore. And it's a proven drug.
Just for the record on this, since this is another of the many rumors going around the echo-chamber.
The drug in question (lapatinib, by Glaxo) is a new drug, which was approved 2 years ago by the FDA to specifically treat a subgroup of breast cancer patients who a) have a specific cancer marker and b) have failed under standard therapy. The drug, used in combination with another class of anti-cancer agents, has been proven to extend the progression-free time of disease. However, there is little statistical evidence that combination treatment with this drug can actually extend survival of patients (see for instance the original, Glaxo-supported study, which people can find
here). Below is a table from that paper, which basically shows that:
- about 27% of women on double therapy have any clinical benefit, vs 18% of women on single therapy (not statistically significant);
- 50% of the women on double therapy had progressed after 8 months, while that time was 4 months for single-terapy recipients;
- survival at 80 weeks was not different between thw two groups.
Now, those extra 4 months of median progression-free time and possibly higher clinical response rate should of course count for something, but considering that the treatment runs at tens of thousands of dollars, it is not completely crazy to think about costs and benefits. Of course, all UK women are still eligible to receive the standard single-drug treatment (which according to the evidence seems to afford similar survival chances), and unlike many American breast cancer patients, do not need to bankrupt their families to do so.
Finally, as I understand it Glaxo has appealed the NHS decision and asked for more time to submit supporting evidence, and the NHS has suspended the implementation of the rule. There really is little doubt that if any new studies show a statistically significant survival benefit (or even just a larger overall clinical benefit) for lapatinib treatment, it will be available to UK patients.